US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Exicure, Inc. - Common Stock (NQ:XCUR)

1.150 -0.030 (-2.54%)
Delayed Quote Updated: 3:59 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exicure, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Exicure, Inc. Reports Second Quarter 2025 Financial Results
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
From Exicure, Inc.
Via Business Wire
News headline image
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Reports First Quarter 2025 Financial Results
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
From Exicure, Inc.
Via Business Wire
News headline image
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Reports Full Year 2024 Financial Results
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
From Exicure, Inc.
Via Business Wire
News headline image
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
From Exicure, Inc.
Via Business Wire
News headline image
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Reports Second Quarter 2024 Financial Results
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Receives Positive Listing Determination from Nasdaq
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Reports First Quarter 2024 Financial Results
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Reports Full Year 2023 Financial Results
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Reports Third Quarter 2023 Financial Results
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
From Exicure, Inc.
Via Business Wire
News headline image
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
From Exicure, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >